Renal safety of biologic and systemic therapies for psoriasis: A systematic review
Published: 13 February 2025| Version 1 | DOI: 10.17632/bydk3yth4f.1
Contributor:
Ryan GengDescription
Psoriasis is a chronic inflammatory disease mainly driven by T-helper-17 dysregulation. Despite increasing use of biologics and nonbiologic systemic therapies for moderate-to-severe psoriasis, data remain limited regarding the renal safety of these therapies.1 This systematic review investigates evidence regarding the impact of biologics and conventional systemic therapies on estimated glomerular filtration rate (eGFR).
Files
Categories
Dermatology